iSpecimen Inc. (NASDAQ:ISPC) Short Interest Update

iSpecimen Inc. (NASDAQ:ISPC) was the recipient of a significant decrease in short interest during the month of January. As of January 15th, there was short interest totaling 311,313 shares, a decrease of 72.6% from the December 31st total of 1,136,955 shares. Based on an average trading volume of 1,172,021 shares, the days-to-cover ratio is currently 0.3 days. Currently, 3.6% of the shares of the stock are sold short. Currently, 3.6% of the shares of the stock are sold short. Based on an average trading volume of 1,172,021 shares, the days-to-cover ratio is currently 0.3 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of iSpecimen in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

Institutional Trading of iSpecimen

A hedge fund recently bought a new position in iSpecimen stock. Scientech Research LLC purchased a new position in iSpecimen Inc. (NASDAQ:ISPC) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 29,488 shares of the company’s stock, valued at approximately $38,000. Scientech Research LLC owned 0.30% of iSpecimen as of its most recent filing with the Securities and Exchange Commission. 13.62% of the stock is owned by institutional investors.

iSpecimen Stock Performance

ISPC stock traded down $0.03 during mid-day trading on Thursday, reaching $0.33. 201,823 shares of the stock traded hands, compared to its average volume of 876,733. iSpecimen has a one year low of $0.26 and a one year high of $3.18. The stock has a market capitalization of $3.21 million, a PE ratio of -0.04 and a beta of 1.83. The business has a 50-day moving average price of $0.39 and a two-hundred day moving average price of $0.81.

iSpecimen (NASDAQ:ISPC) last released its quarterly earnings results on Monday, November 17th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($3.80) by $3.32. iSpecimen had a negative net margin of 343.86% and a negative return on equity of 531.78%. The firm had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $3.33 million.

About iSpecimen

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.